logo
Plus   Neg
Share
Email

BioPharmX: Phase 2b Trial Of BPX-04 Meets Primary, Secondary Endpoints

BioPharmX Corp. (BPMX), a specialty pharmaceutical company focused on medical dermatology products, announced Tuesday positive results from its Phase 2b clinical trial of BPX-04 for papulopustular rosacea.

In pre-market activity, BioPharmX shares were gaining around 62 percent to trade at $1.43.

BPX-04 is a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea.

The randomized, double-blind, vehicle-controlled Phase 2b trial enrolled 206 subjects aged 18 years and above with moderate-to-severe papulopustular rosacea. The study evaluated the safety and efficacy of once daily application of BPX-04, versus a vehicle control over a 12-week treatment period.

The company noted that BPX-04, a 1% minocycline gel, successfully met both the primary and secondary endpoints of the trial. It demonstrated a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear on the Investigator's Global Assessment or IGA scale from baseline to week 12.

David Tierney, BioPharmX CEO, said, "Based on the efficacy and safety profile, we believe BPX-04 has the potential to be the best-in-class treatment for papulopustular rosacea."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Casino operator MGM Resorts International said it was the victim of a data breach in 2019 after a report claimed that the details of more than 10.6 million hotel guests were exposed. Technology website ZDNet reported about the incident late on Wednesday, saying that the personal details of more than 10.6 guests who stayed at MGM Resorts hotels were published on a hacking forum this week. Amid the ongoing troubles with its 737 MAX commercial planes grounding since March 2019, Boeing (BA) has secured a five-year U.S. Air Force contract to sustain and modernize the Global Decision Support System, or GDSS. The financial terms of the deal were not disclosed. The contract was awarded to Tapestry Solutions, part of Boeing Global Services. Reinsurer Swiss Re reported Thursday significantly higher profit in fiscal 2019 driven by higher premiums mainly in property and casualty businesses, despite heavy natural catastrophe losses. The company also said it will propose higher dividend and share buyback of up to 1 billion Swiss Francs. Swiss Re were losing around 4 percent in trading.
Follow RTT
>